TECregen
PrivateLast Round
Seed
Jan 8, 2026
Total Funding Raised
$12.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
TECregen operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Seed round in January 2026.
TECregen is a biotechnology company developing a new class of biologics, called thymopoietics, designed to regenerate the thymus and restore immune function.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TECregen Comparables
Compare TECregen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tolerance Bio, Inc. | 80% | |
| ThymoFox | 79% | |
| Thymmune Therapeutics | 76% |
For institutional investors. Book with your work email.
TECregen Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TECregen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JFG Life Sciences Foundation of the University of Basel | Seed |
| Boehringer Ingelheim Venture Fund | Seed |
| LifeSpan Vision Ventures | Seed |
| CARMA FUND | Seed |
| High-Tech Gründerfonds | Seed |
| Eos | Seed |
| Zurcher Kantonalbank | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 20, 2026
Grew 30% QoQ, from 10 to 13 employees.
- Jan 30, 2026
Dr. Klaas Zuideveld appointed as new Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 10, 2026
TECregen AG appoints Thomas Hanke, PhD, to its Board of Directors in Switzerland on Nov 10th '26, succeeding Martin Raditsch, PhD, as CARMA FUND's representative.
- hiresNov 10, 2026
TECregen AG appoints Elisabeth Svanberg, MD, PhD, as Chief Medical Officer in Switzerland on Nov 10th '26 to support TEC001's preclinical development.
For institutional investors. Book with your work email.
TECregen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TECregen's valuation, stock price, and market status.
Is TECregen a public or private company?
TECregen is a private company.
What is the current stock price of TECregen?
TECregen is a private company, so its shares have no public market price. Caplight tracks TECregen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TECregen worth (valuation)?
Valuation information for TECregen is not publicly available.
Can I buy TECregen stock?
TECregen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TECregen's last funding round?
TECregen's most recent funding round was Seed on January 8, 2026.
Who are the main investors in TECregen?
Key investors in TECregen include Boehringer Ingelheim Venture Fund.
Will TECregen IPO soon?
No public IPO plans have been announced for TECregen.
How can I track TECregen secondary market activity?
Caplight tracks bids, offers, and trades in TECregen's shares on secondary markets.